KyungDong Pharm signed an agreement with OWL Bio for the research, development and commercialization of long-acting injections. The signing ceremony on January 19 was attended by KyungDong Pharm CEO Kim Kyung-hoon, OWL Bio CEO Ahn Tae-gun and other representatives. The collaboration focuses on long-acting treatments for dementia, diabetes and obesity. These injections can substantially reduce dosing frequency, replacing daily treatment with a dose every 1–3 months. OWL Bio is developing products designed to maximize drug loading and sustained activity using its Extina Microsphere drug delivery technology, which incorporates biological peptides and small-molecule drugs into biodegradable microsphere carriers. The MOU was signed approximately one year after KyungDong Pharm invested in OWL Bio, and both companies expect it to strengthen their strategic partnership. CEO Ahn said, “KyungDong Pharm’s decisive investment has helped us achieve tangible research results for improved treatments for diabetes, obesity and dementia. Following this agreement, we plan to submit a clinical trial application to the Ministry of Food and Drug Safety in the second half of this year, enter clinical trials next year and pursue a KOSDAQ listing in the second half of next year. We are also using our drug delivery platform to expand our pipeline into treatments for hepatitis B, smoking cessation and precocious puberty.” CEO Kim said, “Over the past few years, we have actively invested in promising biotechnology ventures to secure future growth. We expect this MOU with OWL Bio to create further synergies. Through close collaboration, we will develop long-acting injections that address patients’ needs and improve convenience.”